Skip to content

Regime for Vitamin D Maintenance in Post-Operative Patients

Regime for Vitamin D Maintenance in Post-Operative Patients (D-ECISIVE) Randomized Controlled Trial

Status
Recruiting
Phases
Phase 3
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT06708741
Acronym
D-ECISIVE
Enrollment
100
Registered
2024-11-27
Start date
2026-01-01
Completion date
2027-06-30
Last updated
2026-05-04

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Sarcopenia

Brief summary

Vitamin D plays a significant part calcium and phosphate haemostasis, thus, intrinsically critical for bone health. Increasing evidence also reveal that insufficient serum vitamin D levels also result in poor muscle health with such individuals having a compromised muscle building potential (4 times slower muscle building). Muscle health is a critical component of a post-surgical patient recovery, with impaired muscle function leading to reduced functional ability, resulting in a poorer quality of life. Poor muscle health also has negative repercussion on survivability, with reduced overall, and disease-specific survival, especially shown in cancer patients. Thus, maintenance of vitamin D levels post-surgery may be more critical than previously thought.

Detailed description

This study is performed in Singapore (outside the US) and the medication, while it is a FDA approved medication, is not manufactured in the US for the trial purpose and the indications of use in this trial is not new. The investigators would be recruiting patients aged 21-65 years who have undergone major surgery (defined by the NICE criteria) and who are able to provide informed consent, accept to take vitamin D supplements post-operatively and have their serum vitamin D levels checked periodically. The investigators will excluded patients who have undergone minor procedures (Table code \<4a), those who have a history of chronic kidney disease/end staged renal failure, known hyperparathyroidism, are non-ambulatory independently and have had known allergies to the commercially available high dose vitamin D formulations. High dose oral vitamin D supplementation (50,000 IU/week for 8 weeks) is the current recommended dose for individuals with vitamin D insufficiency of deficiency and is currently being used for some prehabilitation programmes due to the quick repletion of vitamin D levels to improve muscle gain during the short prehabilitation window prior to surgery. Using the same dose once a month would provide a significantly less vitamin D supplementation, especially with individuals who have had their vitamin D levels repleted in the preoperative phase. This will be compared against a control who are randomised to standard-of-care (SOC) where high dose vitamin D maintenance is not prescribed. The unmet clinical need is the still unknown, unstandardised vitamin D supplementation regime. There are current no clinical consensus on vitamin D supplementation after patients who have undergone major surgery.

Interventions

DRUGVitamin D

High dose oral vitamin D supplementation (50,000 IU/once per month)

Sponsors

Sengkang General Hospital
Lead SponsorOTHER
Hyphens Pharma Pte Ltd
CollaboratorINDUSTRY

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
PREVENTION
Masking
TRIPLE (Caregiver, Investigator, Outcomes Assessor)

Eligibility

Sex/Gender
ALL
Age
21 Years to 65 Years
Healthy volunteers
Yes

Inclusion criteria

* Serum 25-hydroxyvitamin D levels between 30-50ng/ml at 4-6 weeks after operation * aged 21-65 years * ability to provide informed consent * accepts to take vitamin D supplements post-operatively and * have their serum vitamin D levels checked periodically.

Exclusion criteria

* They have undergone minor procedures (Table code \<4a) * have a history of chronic kidney disease/end staged renal failure * have previous history of ureteric/kidney stones * known hyperparathyroidism * are non-ambulatory independently * have had known allergies to the commercially available high dose vitamin D formulations. * Vulnerable personnel would be excluded from the study

Design outcomes

Primary

MeasureTime frameDescription
serum 25-hydroxyvitamin D levels at 3-months post-intervention3 months after initiationserum 25-hydroxyvitamin D levels at 3-months post-intervention

Secondary

MeasureTime frameDescription
serum 25-hydroxyvitamin D levels compared to SOC at 6-months post-intervention.6 months after initiationserum 25-hydroxyvitamin D levels compared to SOC at 6-months post-intervention.
serum 25-hydroxyvitamin D levels compared to SOC at 12-months post-intervention.12 months after initiationserum 25-hydroxyvitamin D levels compared to SOC at 12-months post-intervention.
functional outcome measures at 3-months post-intervention3-months after intiationfunctional outcome measures at 3-months post-intervention
functional outcome measures at 6-months post-intervention6 months after initiationfunctional outcome measures at 6-months post-intervention
functional outcome measures at 12-months post-intervention12 months after initiationfunctional outcome measures at 12-months post-intervention
muscle quality (Ultrasound+MuscleSound™ evaluation) at 3-months post-intervention3 months after intiationmuscle quality (Ultrasound+MuscleSound™ evaluation) at 3-months post-intervention
muscle quality (Ultrasound+MuscleSound™ evaluation) at 6-months post-intervention6 months after initiationmuscle quality (Ultrasound+MuscleSound™ evaluation) at 6-months post-intervention
muscle quality (Ultrasound+MuscleSound™ evaluation) at 12-months post-intervention12 months after initiationmuscle quality (Ultrasound+MuscleSound™ evaluation) at 12-months post-intervention
quality of life (EQ5D-3L) at 3-months post-intervention3 months after intiationquality of life (EQ5D-3L) at 3-months post-intervention
quality of life (EQ5D-3L) at 6-months post-intervention6 months after initiationquality of life (EQ5D-3L) at 6-months post-intervention
quality of life (EQ5D-3L) at 12-months post-intervention12 months after initiationquality of life (EQ5D-3L) at 12-months post-intervention

Countries

Singapore

Contacts

CONTACTFrederick H Koh, FRCS, PhD
frederick.koh.h.x@singhealth.com.sg6930 6000
PRINCIPAL_INVESTIGATORFrederick H Koh, FRCS, PhD

Sengkang General Hospital

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: May 5, 2026